Brown Brothers Harriman & Co. Buys 1,487,998 Shares of Certara, Inc. (NASDAQ:CERT)

Brown Brothers Harriman & Co. grew its stake in Certara, Inc. (NASDAQ:CERT) by 63.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,818,613 shares of the company’s stock after buying an additional 1,487,998 shares during the quarter. Brown Brothers Harriman & Co.’s holdings in Certara were worth $40,668,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the stock. Venturi Wealth Management LLC boosted its stake in Certara by 839.1% in the 4th quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock worth $30,000 after purchasing an additional 2,509 shares during the period. Blue Trust Inc. boosted its position in shares of Certara by 20.9% during the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock worth $56,000 after buying an additional 822 shares during the period. ANTIPODES PARTNERS Ltd grew its holdings in shares of Certara by 204.7% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company’s stock worth $58,000 after buying an additional 3,656 shares in the last quarter. KBC Group NV raised its position in Certara by 64.1% in the 4th quarter. KBC Group NV now owns 7,998 shares of the company’s stock valued at $85,000 after buying an additional 3,125 shares during the last quarter. Finally, GAMMA Investing LLC lifted its stake in Certara by 442.2% in the 4th quarter. GAMMA Investing LLC now owns 8,421 shares of the company’s stock valued at $90,000 after acquiring an additional 6,868 shares in the last quarter. Institutional investors own 73.96% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. William Blair reiterated a “market perform” rating on shares of Certara in a report on Thursday, February 27th. Barclays lifted their price target on shares of Certara from $12.00 to $13.00 and gave the company an “equal weight” rating in a research note on Friday, February 28th. Stephens restated an “overweight” rating and set a $17.00 price objective on shares of Certara in a research note on Thursday, February 27th. Finally, TD Cowen assumed coverage on Certara in a research report on Thursday, February 27th. They issued a “buy” rating and a $16.00 target price on the stock. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Certara has a consensus rating of “Moderate Buy” and an average target price of $15.83.

Certara Trading Down 2.1 %

Shares of NASDAQ:CERT opened at $9.91 on Friday. Certara, Inc. has a 52-week low of $9.41 and a 52-week high of $19.18. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The company has a market capitalization of $1.60 billion, a P/E ratio of -49.55, a price-to-earnings-growth ratio of 9.29 and a beta of 1.60. The company has a 50-day simple moving average of $12.43 and a 200 day simple moving average of $11.44.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.